Skip to main content

A Phase 3, Randomized, Double-blind, Placebo controlled, Parrallel, Fixed Dose Study to Assess the Efficacy, Safety and Tolerability of NBI 98854 for the treatment of Tardive Dyskinesia

Clinical Trial Grant
Duke Scholars

Administered By

Neurology, Movement Disorders

Awarded By

Neurocrine Biosciences, Inc.

Start Date

November 1, 2014

End Date

November 9, 2015
 

Administered By

Neurology, Movement Disorders

Awarded By

Neurocrine Biosciences, Inc.

Start Date

November 1, 2014

End Date

November 9, 2015